EMA begins review of Dynavax's Heplisav

Dynavax Technologies Corp. (NASDAQ:DVAX) said EMA accepted for review an MAA for Heplisav to prevent HBV infection caused by all known subtypes in adults ages 18-70 years and in patients with chronic kidney disease (CKD). The product is a hepatitis B surface antigen (HBsAg) given with immunostimulatory DNA sequences (ISS) that target toll-like receptor 9 (TLR9). ...